Affiliations 

  • 1 Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong, Hong Kong
  • 2 Department of Obstetrics and Gynaecology, Kurume University, Kurume, Japan
  • 3 Ascot Hospital, Remuera, New Zealand
  • 4 Department of Obstetrics-Gynecology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 5 Gynecologic Oncology Unit, Civil Service Hospital, Kathmandu, Nepal
  • 6 Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan
  • 7 Department of Obstetrics and Gynaecology, University of the Philippines, Philippine General Hospital, Manila, Philippines
  • 8 Department of Obstetrics and Gynaecology, KPC Medical College and Hospital, Kolkata, India
  • 9 Gleneagles Penang Hospital, George Town, Malaysia
  • 10 Departemen Obstetri dan Ginekologi, Airlangga University, Surabaya, Indonesia
  • 11 Department of Obstetrics and Gynecology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
J Obstet Gynaecol Res, 2023 Apr;49(4):1230-1243.
PMID: 36726190 DOI: 10.1111/jog.15566

Abstract

BACKGROUND: Despite the introduction of cervical cancer screening and human papillomavirus (HPV) vaccines, the utilization pattern was not standardized. The aim of this study was to elicit the current prevention care in Asia-Oceania.

METHODS: An online questionnaire was circulated to different countries/cities in Asia-Oceania. The primary objective was to evaluate the coverage of HPV vaccination and cervical screening programs. The secondary objectives were to study the structures of these programs. Five case scenarios were set to understand how the respondents manage the abnormal screening results.

RESULTS: Fourteen respondents from 10 countries/cities had participated. Cervical cancer ranked the first in Myanmar and Nepal. About 10%-15% did not have national vaccination or screening program. The estimated coverage rate for vaccination and screening varied from less than 1% to 70%, which the coverage ran in parallel with the incidence and mortality rates of cervical cancer. All regions approved HPV vaccines, although only four provided free or subsidized programs for nonavalent vaccine. Cervical cytology remained the most common screening tool, and 20%-30% relied heavily on visual inspection using acetic acid. The screening age groups varied in different regions. From the case scenarios, it was noted that some respondents tended to offer more frequent screening tests or colposcopy than recommended by international guidelines.

CONCLUSION: This study revealed discrepancy in the practice of cervical cancer prevention in Asia-Oceania especially access to HPV vaccines. There is an urgent need for a global collaboration to eliminate cervical cancer by public education, reforming services, and medical training.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.